SCHEMBL2650122

SCHEMBL2650122

COC(=O)c1ccc(CC(=O)OC(C)(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.54
CYP4A11 Q02928 2/20 0.50
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP4F2 P78329 1/20 0.49
MAPT P10636 3/20 0.48
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA12 O43570 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174700 0.95 LOXL2 (0.50) LOXL2CYP4A11CA1CA2MEN1
SCHEMBL2440071 0.87 SMN1; SMN2 (0.55) LOXL2CYP4A11CA1CA2MEN1
SCHEMBL3135380 0.84 KMT2A (0.53) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL1198228 0.84 LOXL2 (0.63) LOXL2CYP4A11CA1CA2MEN1
SCHEMBL9895432 0.84 CA12 (0.53) CA1CA2MEN1MAPK1KMT2A
SCHEMBL12680354 0.84 CYP4A11 (0.55) LOXL2CYP4A11CA1CA2CYP4F2
SCHEMBL4745549 0.83 ALDH1A1 (0.50) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL19508514 0.83 CYP4F2 (0.56) CYP4A11CA1CA2MEN1KMT2A
SCHEMBL19085086 0.82 MTNR1A (0.47) CYP4A11CYP4F2MAPTLMNASMN1; SMN2
SCHEMBL7177052 0.82 CA12 (0.52) LOXL2CYP4A11CA1CA2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
EP-1594867-B1 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LTD (GB) 2008-04-09 EP disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP disclosed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US disclosed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 LOXL2 4531/4885CYP4A11 121/4885CA1 866/4885
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS IAPP, GPR119, SLC5A1 LOXL2 4535/4885CYP4A11 155/4885CA1 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.